Elicio Therapeutics, Inc.
ELTXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $2.3M | $27.5M | $193,000 |
| Operating income | −$37.7M | −$45.0M | −$35.7M | −$23.7M | −$39.3M | −$55.3M |
| Net income | −$39.6M | −$51.9M | −$35.2M | −$28.2M | −$54.6M | −$80.1M |
| Total assets | $25.9M | $28.2M | $27.1M | $22.7M | $96.5M | $47.3M |
| Total liabilities | $24.2M | $39.5M | $15.8M | $13.7M | $15.0M | $137.8M |
| Equity | $1.6M | −$11.3M | $11.4M | −$102.1M | −$74.5M | −$90.4M |
| EPS (diluted) | $-2.58 | $-4.25 | $-6.96 | $-89.27 | $-1.93 | $-5.43 |
| Shares out. | 16.0M | 10.2M | 30.1M | 30.0M | 30.0M | 15.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −2418.8%
- Return on assets
- −153.0%
- Return on capital (ROCE)
- −212.4%
- Liabilities / assets
- 93.7%
- Debt / equity
- 14.81×
- Book value / share
- $0.10
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -36.34distress
- Accruals / assets
- −10.1%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 1 good- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Actyus Private Equity Sgiic, S.A.Passive (13G)Oct 7, 2025
- Gkcc, LlcActivist (13D)Jun 4, 2025
- Chudnovsky YekaterinaActivist (13D)Mar 7, 2025
- Knoll Capital Management, LlcPassive (13G)Feb 5, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Connelly RobertOfficer — CEO, President and Director | Feb 2, 2026 | Grant | 73,600 | $0.00 |
| Shah PreetamOfficer — See Remarks | Feb 2, 2026 | Grant | 24,000 | $0.00 |
| Demuth PeterOfficer — Chief Scientific Officer | Feb 2, 2026 | Grant | 20,800 | $0.00 |
| Haqq ChristopherOfficer — See Remarks | Feb 2, 2026 | Grant | 25,400 | $0.00 |
| Demuth PeterOfficer — Chief Scientific Officer | Dec 9, 2025 | Option exercise | 362 | $4.41 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.7M | 12.2 | +5.0% |
| Apr 30, 2026 | 1.7M | 11.6 | +14.9% |
| Apr 15, 2026 | 1.4M | 14.3 | +10.0% |
| Mar 31, 2026 | 1.3M | 11.6 | +1.8% |
| Mar 13, 2026 | 1.3M | 6.8 | -1.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Entered a material agreement · Terminated a material agreementMar 16, 2026
- Results of operationsMar 12, 2026
- Results of operationsNov 13, 2025
- Regulation FD disclosure · Other material eventSep 17, 2025
- Other material eventAug 12, 2025
- Results of operationsAug 7, 2025
- Other material eventAug 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.